Frazier Life Sciences Management’s Chinook Therapeutics KDNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-4,345,559
Closed -$167M – 56
2023
Q2
$167M Hold
4,345,559
– – 9.97% 2
2023
Q1
$101M Hold
4,345,559
– – 7.28% 3
2022
Q4
$114M Buy
4,345,559
+80,000
+2% +$1.77M 7.08% 4
2022
Q3
$83.9M Buy
4,265,559
+670,533
+19% +$13.4M 6.46% 4
2022
Q2
$62.9M Buy
3,595,026
+882,985
+33% +$13.9M 5.93% 5
2022
Q1
$44.4M Buy
+2,712,041
New +$36.9M 3.78% 9

Frazier Life Sciences Management's KDNY Position: Q3 2023 in Review

Frazier Life Sciences Management sold out of Chinook Therapeutics (KDNY) in Q3 2023, closing a stake of 4,345,559 shares — an estimated $167M sold.

Frazier Life Sciences Management first reported a position in KDNY in Q1 2022 and held it in 6 quarters. The position peaked at $167M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

  • Frazier Life Sciences Management reported no remaining Chinook Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Frazier Life Sciences Management sold 4,345,559 Chinook Therapeutics shares in Q3 2023, an estimated $167M.
  • Frazier Life Sciences Management first reported a position in Chinook Therapeutics in Q1 2022 and held it in 6 quarters.
  • Frazier Life Sciences Management's Chinook Therapeutics position peaked at $167M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Chinook Therapeutics as of Q3 2023.

Based on Frazier Life Sciences Management's 13F filing for Q3 2023, filed 14 Nov 2023.